New hives drug candidate takes first step in human safety trial
NCT ID NCT07230418
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new oral drug called HRS-3095 in 66 healthy adults aged 18-55. The main goal is to check safety and how the body processes the drug, not to treat any disease. Results will help design future studies for chronic spontaneous urticaria (long-term hives).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Frist Clinical Medicial College of Qingdao University
Qingdao, Shandong, 266555, China